EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer

Ebrahim Esmati, Reza Nazari, Ali Aqamolaei, Afsane Maddah Safaei, Rouhollah Miri, Mohammad Shirkhoda, Amirmohsen Jalaeefar, Samaneh Salarvand, Mahdi Aghili, Farshid Farhan, Nima Mousavi Darzikolaee, Kasra Kolahdouzan und 2 weitere

Clinical and Translational Radiation Oncology · 2026-07 · 59 · 101155

DOI: 10.1016/j.ctro.2026.101155 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Radiation Oncology, 2026-07. Verfasst von Ebrahim Esmati und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

41.4 Gy50.4 GyEsophageal cancerNeoadjuvant chemoradiotherapyRadiation dose

Autor:innen und Institutionen

  • Department of Radiation Oncology, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Anatomical and Clinical Pathology, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Esmati, E., Nazari, R., Aqamolaei, A., Maddah Safaei, A., Miri, R., Shirkhoda, M., Jalaeefar, A., Salarvand, S., Aghili, M., Farhan, F., Mousavi Darzikolaee, N., Kolahdouzan, K., Abyaneh, R., & Ghalehtaki, R. (2026). Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer. Clinical and Translational Radiation Oncology, 59, 101155. https://doi.org/10.1016/j.ctro.2026.101155

Vancouver

Esmati E, Nazari R, Aqamolaei A, Maddah Safaei A, Miri R, Shirkhoda M, et al. Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer. Clinical and Translational Radiation Oncology. 2026;59:101155. doi:10.1016/j.ctro.2026.101155

BibTeX
@article{Esmati2026,
  author = {Esmati, Ebrahim and Nazari, Reza and Aqamolaei, Ali and Maddah Safaei, Afsane and Miri, Rouhollah and Shirkhoda, Mohammad and Jalaeefar, Amirmohsen and Salarvand, Samaneh and Aghili, Mahdi and Farhan, Farshid and Mousavi Darzikolaee, Nima and Kolahdouzan, Kasra and Abyaneh, Romina and Ghalehtaki, Reza},
  title = {Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2026},
  volume = {59},
  pages = {101155},
  doi = {10.1016/j.ctro.2026.101155}
}
Kostenlos starten →